Pre-existing ILD and a decreased PS have been identified as prognostic factors in postmarketing surveys of erlotinib and a meta-analysis of 24 phase III clinical trials of EGFR-TKIs (Gemma et al. 2014; Qi et al. 2015). Here, EGFR is linked to interstitial lung disease.